Multiple preclinical studies show that recombinant IL-22 or IL-22Fc can reduce hepatic steatosis, fibrosis, and inflammation, and attenuate weight gain in diet-induced obese mice (Hwang et al., 2020; Wang et al., 2014d; Yang et al., 2010; Zhang et al., 2024b). Here, IL22 is linked to fatty liver disease.